Peptide
Advancing Peptide Discovery through mRNA Display Innovation
Harnessing mRNA Display Technology for Rapid Macrocyclic Peptide Discovery
A cutting-edge peptide synthesis platform powered by mRNA display technology enables discovery of macrocyclic peptides with exceptional target affinity. Integrated with advanced synthesis and in silico tools, it streamlines the path from sequence to candidate.
- Supreme-diverse libraries (>10^13 variants) via mRNA display
- Supports natural & unnatural amino acid incorporation
- Robust cyclization chemistries for stability and function
- Scalable synthesis with automated purification
- Seamless workflow from design to functional validation
ADCs
Unleash the precision of targeted drug delivery
Transforming Cancer Therapy with Precision and Potency
ADCs combine the specificity of antibodies with the strength of cytotoxic drugs, delivering precision-targeted cancer treatments. Medicilon’s ADC platform offers a seamless end-to-end process, from antibody discovery and linker-payload design to preclinical evaluation and regulatory support. With advanced facilities and regulatory expertise, our ADC solutions minimize side effects while maximizing efficacy.
- Target-specific delivery for enhanced safety
- Advanced payload library for tailored solutions
- IND-enabling studies aligned with FDA and EMA standards
PROTACs
Unlock the power of targeted protein degradation
Harnessing the Power of PROTACs
PROTACs represent the next frontier in treating diseases by degrading harmful proteins instead of merely inhibiting them. Medicilon’s comprehensive PROTAC platform supports every stage, from high-affinity ligand design to in vivo proof-of-concept studies. Our capabilities include advanced E3 ligase expertise, customized linker synthesis, and validated efficacy models.
- Expertise in "undruggable" targets
- Advanced degradation assays and PK/PD analysis
- Regulatory consulting for IND submission
siRNA
Innovative siRNA therapeutics from target to PCC success
Pioneering RNAi Therapeutics for Tomorrow
Medicilon’s siRNA platform accelerates RNA interference research, offering precision-designed, low off-target siRNA solutions. Using advanced tools like siDirect and SNP analysis, we optimize sequences for high potency and efficacy. Our GalNAc-assisted delivery systems and in vitro safety screenings make Medicilon a leader in siRNA therapeutics.
- High-accuracy siRNA design with minimal off-target effects
- Comprehensive in vitro screening for knockdown efficacy
- Proven success in neurotherapeutic applications
Explore the Future of Innovative Therapies
Other Technology Platforms
Transforming Drug Development with Advanced Platforms
Macrocyclic Peptide Platforms
Revolutionizing drug discovery, our macrocyclic peptides provide enhanced stability and binding affinity, unlocking new possibilities in targeting complex proteins.
AI Drug Discovery Platforms
Artificial intelligence transforms drug discovery. Medicilon’s AI platform identifies targets and optimizes leads faster and more efficiently.
Synthetic Biology Platforms
Synthetic biology powers innovative therapies. Our platform supports gene therapy, enzyme design, and biopharmaceutical advancements.
Green Chemistry Platforms
Committed to sustainability, our green chemistry solutions deliver eco-friendly synthesis methods for safer drug development.
Why Partner with Medicilon?
With over 20 years of expertise, Medicilon is a trusted partner in drug discovery. Our integrated platforms and regulatory support empower researchers to bring innovative therapies to life.
